InsidersTradesSigma
Follow the 차바이오텍 stock price and the full directors' dealings record of the company, a publicly traded company based in South Korea. Shares are listed on the KR market, under the oversight of DART (FSS). Operating in the Health Care sector, 차바이오텍 has logged 94 insider filings. Market capitalisation: €826.5bn. The latest transaction was reported on 22 May 2026 (Purchase). Among the most active insiders: 차광렬. All data is openly available.
94
Insider Decl.
n/a
Thresholds
n/a
13 ops.
Buy Volume
€846,999
11 ops.
Sell Volume
22Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 26,989 of 29,057 companies
18.5
score / 100
Value10
Quality27
FCF yld-29%
Earn yld-14%
EV/EBITDA·
ROE-1.8%
Gross mgn29%
Net mgn-8.7%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 22 May 2026
Declarations94 total
25 of 94 declarations
关于 차바이오텍
차바이오텍是一家专注于健康和制药领域的公司，在XKRX市场上市。它专注于开发创新疗法和生物制药解决方案。